BACKGROUND:

Blue light irradiation reduces the proliferation of keratinocytes and modulates T-cell immune response in vitro and has been shown to reduce the severity of psoriasis vulgaris (Pv) in two clinical trials.

OBJECTIVE:

Evaluation of safety and efficacy of long-term UV-free blue light treatment at home for mild Pv.

METHODS:

Forty-seven patients with mild Pv were randomized for receiving high-intensity blue light treatment (HI: 453 nm LED, 200 mW/cm(2), n = 24) and low-intensity treatment (LI: 453 nm LED, 100 mW/cm(2), n = 23) of one Pv plaque for 12 weeks. A contralateral control plaque remained untreated.

RESULTS:

Patient compliance and satisfaction were high. The primary endpoint, change from baseline (CfB) of the Local Psoriasis Severity Index, revealed a significant improvement of the target compared to the control plaques (?CfB for the HI group: -0.92 ± 1.10, p = 0.0005; for the LI group: -0.74 ± 1.18, p = 0.0064).

CONCLUSION:

UV-free blue light home treatment is safe and improves Pv plaques.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT02004847.

© 2015 S. Karger AG, Basel.